Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
Alexion’s track record has been disappointing so far. Over the four trailing quarters, the company has posted an average earnings surprise of -0.87%, having beaten estimates in only one quarter and missing the same in the rest.
Currently, Alexion has a Zacks Rank #5 (Strong Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion beats on earnings expectations. Our consensus called for EPS of 91 cents, and the company reported EPS of 92 cents (these figures include stock-based compensation expense).
Revenue: Revenues were also above expectations. Alexion posted revenues of $753 million, compared to our consensus estimate of $743 million.
Key Stats: Soliris continues to drive revenues at Alexion. Strensiq and Kanuma sales are also picking up to global launches. The company revised its 2016 outlook. The company expects adjusted earnings per share in the range of $4.50 to $4.65 range. The company also expects revenues in the range of $3.05–$3.1 billion.
Check back later for our full write up on this Alexion earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Image: Bigstock
Alexion (ALXN) Beats on Q2 Earnings and Revenues
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
Alexion’s track record has been disappointing so far. Over the four trailing quarters, the company has posted an average earnings surprise of -0.87%, having beaten estimates in only one quarter and missing the same in the rest.
Currently, Alexion has a Zacks Rank #5 (Strong Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion beats on earnings expectations. Our consensus called for EPS of 91 cents, and the company reported EPS of 92 cents (these figures include stock-based compensation expense).
Revenue: Revenues were also above expectations. Alexion posted revenues of $753 million, compared to our consensus estimate of $743 million.
Key Stats: Soliris continues to drive revenues at Alexion. Strensiq and Kanuma sales are also picking up to global launches. The company revised its 2016 outlook. The company expects adjusted earnings per share in the range of $4.50 to $4.65 range. The company also expects revenues in the range of $3.05–$3.1 billion.
ALEXION PHARMA Price
ALEXION PHARMA Price | ALEXION PHARMA Quote
Check back later for our full write up on this Alexion earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>